MiNA Therapeutics Signs a Research Collaboration with AstraZeneca to Evaluate Therapies for Metabolic Diseases

 MiNA Therapeutics Signs a Research Collaboration with AstraZeneca to Evaluate Therapies for Metabolic Diseases

AstraZeneca and Daiichi Report the US FDA’s Acceptance of BLA for Trastuzumab deruxtecan (DS-8201) and Granted Priority Review

Shots:

  • MiNA and AstraZeneca will conduct in vitro and in vivo studies allowing the development of saRNA therapies for Metabolic Diseases. Post the completion of the studies, AstraZeneca will have an option to further develop saRNA therapies for its identified targets
  • The focus of the collaboration is to combine MiNA’s expertise in the discovery and development of saRNA therapies with AZ’s insights of identifying and developing breakthrough therapies for metabolic diseases
  • Small activating RNA (saRNAs) are therapies involved in modality to upregulate genes with the capability to access disease-relevant targets

Click here to read full press release/ article | Ref: MiNA Therapeutics | Image: Signbox

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post